Intestinal Research · 2018 · 12 citations · 16 references
MedicineClinical SciencesImmunologyGastroenterologyInflammationMucosal ImmunologyCrohn Disease PharmacotherapyGastrointestinal InflammationInflammatory BiomarkersInflammatory Bowel DiseaseMucosal InflammationOutcome AssessmentEndoscopic Inflammation AssessmentInflammatory Bowel Disease Activity AssessmentInflammatory Bowel Disease EndoscopyInflammatory Bowel Disease TherapyLoss Of ResponseMucosal Healing ResponseReceiver Operating Characteristic AnalysisTrough Concentrations
BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could become a predictor of mucosal healing (MH) (Study 2). METHODS: Study 1 was conducted in 108 patients, including those with LOR and remission to compare ATI and TLI in discriminating the 2 conditions based on receiver operating characteristic (ROC) curve analyses. Study 2 involved 35 patients who were evaluated endoscopically. RESULTS: =0.032). CONCLUSIONS: TLI is better than ATI for clinically diagnosing LOR, and a correlation was observed between TLI and colonic MH.
16
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations
Development of a Crohn's Disease Activity Index
William R. Best, Jack M. Becktel, John W. Singleton et al. · Gastroenterology · 1976 · 3.2K citations
Veterinary Medicine, Clinical Sciences, Internal Medicine +12
Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden et al. · Arthritis & Rheumatism · 1998 · 1.6K citations